Alector stock (ticker symbol ALEC) represents a clinical-stage biotechnology enterprise specializing in immuno-neurology and neurodegenerative disease treatments, meaning it has no operational or financial connection to the sport of football. Any perceived overlap in terminology stems entirely from distinct acronym usage or unrelated private entities, as the publicly traded biopharmaceutical equity focuses exclusively on medical research and drug development rather than athletic leagues or sporting industries.